Indication

As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Medicine details

Medicine name:
rucaparib (Rubraca)
SMC ID:
SMC2224
Pharmaceutical company
Clovis Oncology UK Limited
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q1 2020
SMC meeting date:
Q1 2020
Patient group submission deadline:
04 November 2019